Skip to main content
S&P 5007,801.77-0.22%DOW51,179.87-0.66%NASDAQ27,538.69-0.22%BTC$83,372.00-2.51%ETH$2,574.91-4.55%GOLD$4,130.50-0.25%OIL$89.24+1.09%
Smart Investors Daily
SID Premium
OB

NASDAQ · OBIO

Orchestra BioMed Holdings, Inc.

Healthcare · Biotechnology

$5.66

Down-$0.18 (-3.08%)

Updated Oct 8, 2026, 4:07 AM

SID Score

6.6/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
257.76M
P/E ratio
-2.51
Dividend yield
0.00%
52-week range
$2.66 – $6.50
Volume
241.25K
Avg. volume
309.78K

Price performance · OBIO

OBIO price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 7, 2026

OBIO closed at $5.66 after 21 trading sessions, up 3.85% for the selected period.

Last close
$5.66
Period change
+3.85%
Period low
$5.45
Period high
$6.35
Daily close
View OHLC price history
OBIO OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 7, 2026$5.79$5.859$5.64$5.66241.25K
Oct 6, 2026$6.05$6.12$5.82$5.84213.12K
Oct 5, 2026$5.89$6.09$5.7898$6.03284.8K
Oct 2, 2026$6.40$6.44$5.77$5.95421.09K
Oct 1, 2026$6.27$6.50$6.23$6.35389.94K
Sep 30, 2026$6.09$6.29$6.00$6.22277.39K
Sep 29, 2026$5.89$6.09$5.83$6.08237.09K
Sep 28, 2026$5.95$5.95$5.80$5.89177.45K
Sep 25, 2026$5.99$6.17$5.86$5.95248.77K
Sep 24, 2026$5.90$6.05$5.75$5.95262.89K
Sep 23, 2026$6.10$6.20$5.90$5.93242.36K
Sep 22, 2026$6.15$6.48$6.0525$6.22343.05K
Sep 21, 2026$6.04$6.29$5.85$6.25433.19K
Sep 18, 2026$5.74$6.30$5.71$6.081.14M
Sep 17, 2026$6.03$6.26$5.73$5.78411.8K
Sep 16, 2026$6.05$6.28$5.93$6.01297.2K
Sep 15, 2026$6.00$6.13$5.93$6.04228.74K
Sep 14, 2026$6.07$6.20$5.74$5.90383.62K
Sep 11, 2026$5.87$6.25$5.7604$6.12464.46K
Sep 10, 2026$5.845$6.08$5.68$5.81761.62K
Sep 9, 2026$5.31$5.4599$5.2609$5.45198.56K

Latest OBIO news

The latest Smart Investors Daily articles mentioning OBIO.

Stock researchCompany · Overview

OBIO research

Overview

Company profile and research snapshot.

Company profile

Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$12.00
Implied upside
—
Analysts
13
OBIO recent ratings
DateFirmRatingTarget
Sep 15, 2026B. Riley SecuritiesBuy—
Sep 10, 2026BTIGBuy—
Aug 11, 2026Piper SandlerOverweight—
May 19, 2026B. Riley SecuritiesBuy—
May 14, 2026HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 16, 2026

Orchestra BioMed Announces AVIM Therapy to Be Featured in Two Sessions at HRX Live 2026

Sessions will highlight Orchestra BioMed's collaboration with Medtronic and explore the potential for AVIM Therapy to treat hypertensive heart disease in pacemaker-indicated patients and beyondNEW HOPE, Pa., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) ("Orchestra BioMed" or the "Company"), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, today announced

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By